Added feature offers cost savings and the ability to reduce carbon footprint, company says.
Suvoda LLC, a clinical trial technology company, announced a new advanced drug optimization feature as part of its latest interactive response technology (IRT) release. According to the company, this feature offers sponsors of clinical drug trials improved drug supply management, delivering cost savings, and helping companies to reduce their carbon footprint. In the past, supply strategies depended on static quantities of initial drug shipments and buffers, often leading to excessive orders to ensure enough medication is available during a trial.
"Suvoda's new enhancement is an example of how we listen to the needs of our customers and deliver tools that help our sponsors and partners," said Lisa Li, director of IRT product management, Suvoda. "We heard from drug supply managers that they were concerned about the impact of drug oversupply across the entire supply chain, including raw materials, manufacturing, storage, shipping, and packing materials. Helping study managers fine-tune supply can maximize trial resources and increase efficiencies."
Reference: Suvoda Introduces Advanced Drug Optimization for IRT to Improve Accuracy of Clinical Trial Drug Supply Management. PR Newswire. October 12, 2023. Accessed October 13, 2023. https://www.prnewswire.com/news-releases/suvoda-introduces-advanced-drug-optimization-for-irt-to-improve-accuracy-of-clinical-trial-drug-supply-management-301951747.html
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.